Exploring CAR-PBMCs: A Novel Strategy Against EGFR-Positive Tumor Cells

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Feb 26

PMID 40002679

Authors

Alexandru Tirziu

Oana-Isabella Gavriliuc

Maria-Florina Bojin

Virgil Paunescu

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown significant promise in treating hematological malignancies, yet its application in solid tumors, particularly those expressing the epidermal growth factor receptor (EGFR), remains limited. This study investigates the potential of CAR-engineered peripheral blood mononuclear cells (PBMCs) as a novel adoptive cell therapy against EGFR-positive cancers. Lentiviral transduction at an MOI of 50 was performed to generate specific anti-EGFR second generation CAR-effector cells. The transduced PBMCs were stimulated with cytokines and CD3/CD28 beads to enhance their proliferation and activation. Flow cytometric and real-time cell analysis were performed at various effector-to-target ratios to explore the cytotoxic potential of CAR-PBMCs. CAR-PBMCs exhibited improved targeting and cytotoxicity against EGFR-positive cancer cell lines MDA-MB-468 and SK-BR-3, compared to untransduced controls, with unsignificant effects on allogeneic PBMCs. CAR-PBMCs hold considerable potential as a therapeutic strategy for EGFR-positive solid tumors, warranting further clinical investigation.

References

Di S, Li Z . Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Sci China Life Sci. 2016; 59(4):360-9. DOI: 10.1007/s11427-016-5025-6. View

Taylor B, Balko J . Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Front Immunol. 2022; 13:844866. PMC: 8920040. DOI: 10.3389/fimmu.2022.844866. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Labbe R, Vessillier S, Rafiq Q . Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses. 2021; 13(8). PMC: 8402758. DOI: 10.3390/v13081528. View

Heczey A, Liu D, Tian G, Courtney A, Wei J, Marinova E . Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014; 124(18):2824-33. PMC: 4215313. DOI: 10.1182/blood-2013-11-541235. View

Drent E, Poels R, Ruiter R, van de Donk N, Zweegman S, Yuan H . Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Clin Cancer Res. 2019; 25(13):4014-4025. PMC: 7477921. DOI: 10.1158/1078-0432.CCR-18-2559. View

Sun Z, Chen F, Meng F, Wei J, Liu B . MHC class II restricted neoantigen: A promising target in tumor immunotherapy. Cancer Lett. 2017; 392:17-25. DOI: 10.1016/j.canlet.2016.12.039. View

Hadiloo K, Tahmasebi S, Esmaeilzadeh A . CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023; 23(1):86. PMC: 10165596. DOI: 10.1186/s12935-023-02923-9. View

Lin H, Cheng J, Mu W, Zhou J, Zhu L . Advances in Universal CAR-T Cell Therapy. Front Immunol. 2021; 12:744823. PMC: 8526896. DOI: 10.3389/fimmu.2021.744823. View

10.

Camidge D, Pao W, Sequist L . Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11(8):473-81. DOI: 10.1038/nrclinonc.2014.104. View

11.

Hong D, Sloane D . Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases. Ann Allergy Asthma Immunol. 2019; 123(1):35-41. DOI: 10.1016/j.anai.2019.04.015. View

12.

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

13.

Martin-Otal C, Navarro F, Casares N, Lasarte-Cia A, Sanchez-Moreno I, Hervas-Stubbs S . Impact of tumor microenvironment on adoptive T cell transfer activity. Int Rev Cell Mol Biol. 2022; 370:1-31. DOI: 10.1016/bs.ircmb.2022.03.002. View

14.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

15.

Li Y, Rezvani K, Rafei H . Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer. Immunol Rev. 2023; 320(1):217-235. PMC: 10841677. DOI: 10.1111/imr.13255. View

16.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

17.

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius J, Sievers S . Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther. 2017; 25(11):2452-2465. PMC: 5675490. DOI: 10.1016/j.ymthe.2017.07.013. View

18.

Weinkove R, George P, Dasyam N, McLellan A . Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunology. 2019; 8(5):e1049. PMC: 6511336. DOI: 10.1002/cti2.1049. View

19.

Park M, Kim J . Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer. Toxicol Res. 2024; 40(3):335-348. PMC: 11187026. DOI: 10.1007/s43188-024-00233-4. View

20.

Abd-Aziz N, Poh C . Development of Peptide-Based Vaccines for Cancer. J Oncol. 2022; 2022:9749363. PMC: 8941562. DOI: 10.1155/2022/9749363. View